13F
← All fund report cards

ANTIPODES PARTNERS Ltd

13F equity value
$5.2B
Positions
126
Top 10 concentration
35.3%
Quarters / total new picks
32 / 259
13F equity value over time
$0M$244B$489B2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +3.0% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 46.9% of quarters (excess t = 0.73, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
+2.6%
t-stat
0.73
Quarterly win rate
47%
Annualized excess
+1.1%
$1 → follow vs universe
$2.26 vs $2.09
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220331: universe 1.38720220630: universe 1.28520220930: universe 1.38120221231: universe 1.28220230331: universe 1.35120230630: universe 1.30320230930: universe 1.47920231231: universe 1.54520240331: universe 1.58020240630: universe 1.72320240930: universe 1.70820241231: universe 1.59420250331: universe 1.73820250630: universe 1.79320250930: universe 2.01620251231: universe 2.085 20180331: follow 1.00620180630: follow 1.00220180930: follow 1.11620181231: follow 1.24920190331: follow 1.23020190630: follow 1.25120190930: follow 1.47020191231: follow 1.40520200331: follow 1.65420200630: follow 2.18520200930: follow 2.50720201231: follow 2.31320210331: follow 2.16920210630: follow 2.16620210930: follow 2.23220211231: follow 1.99120220331: follow 1.92420220630: follow 1.52720220930: follow 1.59620221231: follow 1.52220230331: follow 1.52220230630: follow 1.52420230930: follow 1.65020231231: follow 1.62520240331: follow 1.60120240630: follow 1.83920240930: follow 1.82620241231: follow 1.85920250331: follow 1.94820250630: follow 1.96420250930: follow 2.13320251231: follow 2.261 0.84 1.77 2.71 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 126 · 2026 Q1

Ticker Value Weight QoQ
AMZN $249M
4.8%
ADD
AEP $237M
4.6%
HOLD
MSFT $197M
3.8%
ADD
EXC $184M
3.5%
ADD
MRK $173M
3.3%
TRIM
SRE $167M
3.2%
ADD
FER $166M
3.2%
ADD
B $165M
3.2%
TRIM
BKD $156M
3.0%
HOLD
AEE $140M
2.7%
ADD
HCA $138M
2.7%
HOLD
COF $136M
2.6%
TRIM
TTE $133M
2.6%
ADD
CCI $132M
2.5%
ADD
HTO $132M
2.5%
ADD
ETR $131M
2.5%
ADD
NVDA $124M
2.4%
NEW
WTRG $122M
2.3%
TRIM
FMX $111M
2.1%
ADD
KEYS $107M
2.1%
TRIM

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.